LymeX Diagnostics Prize Announces Phase 3 Winners, Paving the Way for Advanced Lyme Disease Diagnostics

LymeX Diagnostics Prize Announces Phase 3 Winners

The LymeX Diagnostics Prize, a significant initiative aimed at accelerating the development of Lyme disease diagnostics, has announced its Phase 3 winners. This phase of the competition, supported by a more than $10 million pledge from the Steven & Alexandra Cohen Foundation, focuses on nurturing diagnostics towards FDA review and clearance. The winners, each awarded $420,000, have developed innovative solutions for the early detection and treatment tracking of Lyme disease.

The Winning Teams and Their Innovations

• BlueArc Biosciences Inc. (La Jolla, California): Developed an ultrasensitive and specific blood test for the direct detection of B. burgdorferi infection from the first symptoms of Lyme disease using standard laboratory equipment.
• Drexel University College of Medicine (Philadelphia): Created a small-volume serum test using glycan biomarkers to detect active Lyme disease infection and track treatment response.
• HelixBind Inc. (Marlborough, Massachusetts): Designed a direct-from-blood molecular assay that can detect DNA from intact Borrelia spirochetes utilizing a proprietary, readily automated sample-to-answer process.
• Massachusetts General Hospital (Boston): Developed a plasma and extracellular fluid test depleting human background material from samples and detecting low-abundance nucleic acid from tick-borne pathogens.
• Northwestern University Feinberg School of Medicine (Chicago): Created a test using monoclonal antibodies in conjunction with both immuno-PCR and lateral flow to rapidly detect a unique B. burgdorferi biomarker in blood and urine.

Phase 3 Overview and Support

From May to October 2024, the teams benefited from webinar modules, mentorship, and networking opportunities. They also received non-financial in-kind support from industry leaders Labcorp and Quest Diagnostics, enhancing their understanding of the diagnostics industry and clinical laboratory operations. The competition's judging panel, composed of experts in various relevant fields, evaluated submissions based on official Phase 3 evaluation criteria, including engagement with the FDA, analytical performance data, and clinical performance study protocols.

Looking Ahead: Phase 4

Phase 4 of the LymeX Diagnostics Prize will focus on supporting clinical validation studies and completing regulatory submissions to the FDA, with up to $3 million in prizes awarded. The competition anticipates additional prizes for FDA clearance, marking a significant step forward in the fight against Lyme disease.

This initiative represents a critical advancement in the development of effective diagnostics for Lyme disease, offering hope for improved detection and treatment outcomes for patients worldwide.